Longitudinal pathways of exclusive and polytobacco smokeless use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1-3 (2013-2016).


Journal

Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612

Informations de publication

Date de publication:
05 2020
Historique:
received: 14 01 2020
revised: 22 01 2020
accepted: 27 01 2020
entrez: 24 4 2020
pubmed: 24 4 2020
medline: 3 6 2021
Statut: ppublish

Résumé

Use of smokeless tobacco (SLT) with other tobacco products is growing, yet gaps in understanding transitions among SLT and other product use remain. The aim of this study is to examine cross-sectional prevalence and longitudinal pathways of SLT use among US youth (12-17 years), young adults (18-24 years) and adults 25+ (25 years and older). Data were drawn from the first three waves (2013-2016) of the Population Assessment of Tobacco and Health Study, a nationally representative, longitudinal cohort study of US youth and adults. Respondents with data at all three waves (youth, n=11 046; young adults, n=6478; adults 25+, n=17 188) were included in longitudinal analyses. Young adults had the highest current SLT use compared with other age groups. Among Wave 1 (W1) past 30-day youth and young adult SLT users, most were SLT and cigarette polytobacco users compared with adults 25+, who more often used SLT exclusively. Among W1 exclusive SLT users, persistent exclusive use across all three waves was more common among adults 25+, while transitioning from exclusive SLT use to SLT polytobacco use at Wave 2 or Wave 3 was more common among youth and young adults. Among W1 SLT and cigarette polytobacco users, a common pathway was discontinuing SLT use but continuing other tobacco use. Our results showed distinct longitudinal transitions among exclusive and SLT polytobacco users. Deeper understanding of these critical product transitions will allow for further assessment of population health impact of these products.

Identifiants

pubmed: 32321851
pii: tobaccocontrol-2020-055628
doi: 10.1136/tobaccocontrol-2020-055628
pmc: PMC7534605
mid: NIHMS1553428
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

s170-s177

Subventions

Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: WMC reports long-term stock holdings in General Electric Company, 3M Company, and Pfizer Incorporated, unrelated to this manuscript. No financial disclosures were reported by the other authors of this paper

Références

Am J Public Health. 2013 May;103(5):923-30
pubmed: 23488521
Tob Control. 2020 May;29(Suppl 3):s163-s169
pubmed: 32321850
Prev Med. 2014 May;62:14-9
pubmed: 24440684
MMWR Morb Mortal Wkly Rep. 2017 Jun 16;66(23):597-603
pubmed: 28617771
Tob Control. 2020 May;29(Suppl 3):s155-s162
pubmed: 32321849
Addiction. 2003 Sep;98(9):1183-9
pubmed: 12930201
MMWR Morb Mortal Wkly Rep. 2015 Oct 02;64(38):1066-70
pubmed: 26421418
JAMA. 2015 Nov 3;314(17):1871-3
pubmed: 26502219
Nicotine Tob Res. 2016 May;18(5):817-26
pubmed: 26136525
Tob Control. 2014 Mar;23(2):107-12
pubmed: 23117999
Tob Control. 2020 May;29(Suppl 3):s139-s146
pubmed: 32321847
Nicotine Tob Res. 2016 Aug;18(8):1740-8
pubmed: 26995793
MMWR Morb Mortal Wkly Rep. 2016 Jul 15;65(27):685-91
pubmed: 27416365
Vital Health Stat 2. 1969 Jan;(31):1-24
pubmed: 5306564
MMWR Morb Mortal Wkly Rep. 2017 Nov 10;66(44):1209-1215
pubmed: 29121001
PLoS One. 2014 Dec 23;9(12):e113196
pubmed: 25535739
J Adolesc Health. 2014 Jan;54(1):47-53
pubmed: 24060573
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):629-633
pubmed: 29879097
J Stud Alcohol Drugs. 2008 Sep;69(5):709-17
pubmed: 18781246
Am J Health Behav. 2015 Mar;39(2):277-84
pubmed: 25564840
Tob Control. 2019 Nov;28(6):663-668
pubmed: 30297373
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
MMWR Morb Mortal Wkly Rep. 2016 Apr 15;65(14):361-7
pubmed: 27077789
J Adolesc Health. 2014 Jan;54(1):54-60.e9
pubmed: 24074604
Nicotine Tob Res. 2013 Jan;15(1):88-92
pubmed: 22529222
Prev Med. 2015 Dec;81:251-7
pubmed: 26361752
N Engl J Med. 2017 Jan 26;376(4):342-353
pubmed: 28121512
BMC Public Health. 2015 Mar 18;15:258
pubmed: 25849604
Tob Control. 2020 May;29(Suppl 3):s147-s154
pubmed: 32321848
Am J Public Health. 2010 Jan;100(1):78-87
pubmed: 19910355
Prev Med. 2003 May;36(5):575-84
pubmed: 12689803

Auteurs

Eva Sharma (E)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States EvaSharma@westat.com.

Kathryn C Edwards (KC)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States.

Michael J Halenar (MJ)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States.

Kristie A Taylor (KA)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States.

Karin A Kasza (KA)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

Hannah Day (H)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Lisa D Gardner (LD)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Gabriella Anic (G)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Maansi Bansal-Travers (M)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

Jean Limpert (J)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Hoda T Hammad (HT)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Nicolette Borek (N)

Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, United States.

Heather L Kimmel (HL)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, United States.

Wilson M Compton (WM)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, United States.

Andrew Hyland (A)

Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.

Cassandra A Stanton (CA)

Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States.
Department of Oncology, Georgetown University Medical Center, Washington, DC, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH